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INTRODUCTION
Papillary thyroid microcarcinoma (PTMC) is defined as a papil-
lary thyroid carcinoma that’s equal to or less than 1.0 cm at the
greatest dimension according to the World Health Organization
classification system for thyroid tumors (1). The prevalence of
PTMC in the general population with no thyroid disease is report-
edly high at 3-36%, according to autopsy studies (2-4). The major-
ity of PTMCs are not palpable and show an asymptomatic
course (5). High-resolution thyroid ultrasonography and finenee-
dle aspiration cytology (FNAC) under ultrasound guidance have
recently enabled making an accurate diagnosis of PTMC, which
may explain why the reported incidence of PTMC is increasing
(6). Although PTMC generally has a favorable prognosis, the
tumor may show locoregional recurrence and distant metas-
tases (7-10). For PTMC patients, the reported incidence of
lymph node metastasis is as high as 40%, and these occur main-
ly in the central compartment of the neck (2, 3, 11). However,
the prognostic factors that can differentiate silent PTMC from
potentially aggressive PTMC remain unclear.
One of the major issues for the treatment of PTMC is whether
central neck lymph node dissection (CND) should be routinely
Objectives. It remains unclear as to whether routine central neck dissection (CND) is necessary when performing surgery
to treat patients with papillary thyroid microcarcinoma (PTMC). To determine the necessity for routine CND in
PTMC patients, we reviewed the clinicopathologic and laboratory data of the patients of PTMC.
Methods. Between September 2001 and July 2005, 101 patients with PTMC and clinical N0 disease were retrospectively
reviewed. The study cohort was devided into groups: the total thyroidectomy plus CND group (the CND group,
N=48) and the total thyroidectomy without CND group (the no CND group, N=53). The serum stimulated thy-
roglobulin (Tg) levels were measured after surgery and prior to radioactive iodine ablation therapy (RAI) and at
6-12 months after RAI. Pathology, the Tg levels and recurrence data were compared between the 2 groups.
Results. Central nodal metastases were found in 18 of the 48 CND patients (37.5%). The incidence of Tg levels >5 ng/mL
at RAI was higher in the no CND patients and in the 18 node-positive CND patients compared with the 30 node-
negative CND patients (22-24% vs. 3%, respectively, P=0.020-0.058). The difference when performing a similar
comparison using a >2 ng/mL Tg threshold level showed no significance (10-11% vs. 4%, respectively, P>0.1).
Two of the no CND patients and one node-positive CND patient had recurrences in the thyroid bed or lateral neck
during a mean follow-up of 24 months.
Conclusion. The data showed that occult metastasis to the central neck is common in PTMC patients. A CND provides
pathologic information about the nodal metastases, and it potentially provides guidance for planning the postoper-
ative RAI. However, the long-term benefit of CND on recurrence and survival remains somewhat questionable.
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Original Articleperformed during the initial operation. While CND is not gen-
erally performed due to the excellent prognosis of PTMC, some
reports have recommended performing routine CND even in
PTMC patients with no clinical nodal metastases (12, 13).
The present study reviewed the surgery, pathology, laboratory
and follow-up data of 101 patients who underwent surgery for
PTMC. In order to determine the clinical necessity of performing
CND in PTMC patients, the patients were analyzed in terms of
those who underwent CND (CND) and those who did not (no
CND).
MATERIALS AND METHODS
Patient population and study design
The clinical data was reviewed on 106 PTMC patients who under-
went total thyroidectomy between September 2001 and July
2005. The pathology of all the patients were papillary carcinoma,
as indicated by fine needle aspiration cytology that was guided
by high-resolution ultrasonography, and the aspiration patholo-
gy was confirmed by the surgical pathology. Preoperative eval-
uation included taking a clinical history and a physical exami-
nation, thyroid function tests and radiography of the thorax and
ultrasonography. The ultrasonograpnic examinations were per-
formed preoperatively by the same experienced radiologist (J.H.L)
in order to evaluate lymph node metastasis. Five patients who
were preoperatively suspected of having cervical lymph node
metastasis and who underwent therapeutic neck lymph node
dissection were excluded from the study. Thus, 101 patients with
primary tumor sizes ≤1.0 cm and no preoperative evidence of
nodal metastases were finally included in the study.
For analysis, the patients were divided into 2 groups: the
total thyroidectomy without CND group (the no CND group,
N=53) and the total thyroidectomy plus CND group (the CND
group, N=48) (Table 1). The study cohort was not randomized
and the decision to perform CND was made by both the sur-
geon and the patient. The pathology, laboratory findings and
recurrence were compared between the two groups. This study
was reviewed and approved by the Institutional Review Board
of the Asan Medical Center and informed consent was waived. 
Central node dissection
CND was carried out in a conventional manner and microdis-
section methods were not used (14). Node clearance was per-
formed cranially to both superior thyroid arteries and the pyra-
midal lobe, caudally to the innominate vein, laterally to the carotid
sheaths and dorsally to the prevertebral fascia (5). The thymus
was commonly preserved by separating it from the central nodes.
The central compartment was divided into 4 node sites: the pre-
tracheal site, the ipsilateral site, the contralateral paratracheal site
and the superior mediastinal site below the sternal notch. Particular
attention was given to identifying the parathyroid glands, and
parathyroid autotransplantation was carried out as required, not
on principle.
Observation of the pathology and complications
The pathology was carefully reviewed with focusing on the pri-
mary tumor size and multifocality, extrathyroidal extension and
lymph node metastases. The prevalence of central nodal metas-
tases was obtained from the CND patients. The medical records
regarding the surgical complications were thoroughly reviewed.
Hypocalcemia was defined as the need for exogenous calcium
replacement in order to maintain a normal range of serum total
calcium (8-10.4 mg/dL) or to eliminate the clinical signs and symp-
toms of hypocalcemia. Hypocalcemia was considered permanent
when calcium replacement was necessary for longer than 12
months.
Measurement of serum thyroglobulin and the follow-up 
All the patients received radioactive iodine ablation therapy (RAI)
with 2.78-5.55 GBq
131I at 5-6 weeks after surgery. Prior to RAI,
the serum thyroid-stimulating hormone (TSH) level was elevat-
ed to >30 mU/L, and then the serum levels of stimulated Tg
(ablation-Tg) and anti-Tg antibody were measured. A whole
body scan (WBS) using 148 MBq
131I was performed at 5-7 days
and at 6-12 months after RAI with a simultaneous measurement of
the serum stimulated Tg (control-Tg). The serum Tg levels were
measured using a solid phase two-site immunoradiometric assay
kit (ELSA-hTG
�, Schering-CIS Bio International, Gif/Yvette,
France) as previously described (15). The detection limit of thy-
roglobulin was 1.0 ng/mL. The anti-Tg levels were measured
using radioligand assays (HENNING test anti-Tg; BRAHMS
Diagnostica, Berlin, Germany). Anti-Tg values above 100 U/mL
were considered positive. When the control-Tg level was above
2 ng/mL, then neck ultrasonography with or without fine nee-
dle aspiration cytology was performed to localize the potential-
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Variables no CND group
(N=53)
CND group
(N=48)
P-value
�
Gender (male:female)
Mean age (years)
Mean size of primary tumor (mm)
Multifocality (single:multiple)
Extrathyroidal extension
Metastases to the central neck
Transient hypocalcemia (%)
Permanent hypocalcemia (%)
Transient vocal cord palsy
11:42
48±9.9
7.3±2.3
12:41
31/53
N/A
6 (11.3)
1 (1.9)
0
6:42
52±12.0
6.8±2.1
15:33
22/48
18/48
8 (16.7)
0
1 (2.1)
0.30
0.10
0.18
0.37
0.24
0.78
0.48
Table 1. The clinical characteristics, pathologic findings and com-
plications of the PTMC patients who underwent (the CND group) or
did not undergo (the no CND group) routine central neck dissection*
PTMC: papillary thyroid microcarcinoma; CND: central neck dissection.
* None of the patients had evidence of cervical nodal metastases prior to surgery.
�Fisher’s exact test except for age and the primary tumor size (t-test).ly malignant thyroid lesions.
Statistical analysis
The t-test was used to analyze the mean differences of the patholog-
ic findings and the other clinical parameters between the groups.
Fisher’s exact test or 
2 test was used to investigate differences
among the categorical data. A P-value of less than 0.05 was deemed
to indicate a significant difference. SPSS software (version 12.0,
SPSS, Inc., Chicago, IL, USA) was used for analysis of the data.
RESULTS
The study cohort consisted of 17 men and 84 women, with a
mean age of 49.8 years (range: 23 to 76 years) (Table 1). The CND
and no CND groups were similar in terms of gender and the age
distribution. The mean follow-up time after surgery was 24.4
months (range: 13-55 months).
Complications and the pathologic findings
Both the CND and no CND groups had similar complication
rates (P>0.1). The overall incidence of hypocalcemia was 15 of
101 patients (14.9%), of whom only one patient had permanent
hypocalcemia. Transient vocal cord palsy occurred in only one
CND patient. Other complications (e.g., bleeding, hematoma and
seroma) were not noted in either group (data not shown). No
pathologic difference was found between the groups. The mean
size and the presence of multifocality and an extrathyroidal exten-
sion of the primary tumors were the same for both groups. For
the CND group, 18 of 48 patients (37.5%) had central nodal
metastasis. 
Serum thyroglobulin levels and recurrence
The levels of ablation-Tg and control-Tg were compared be-
tween the no CND patients and the CND patients with or with-
out central nodal metastases (Fig. 1). Three no CND patients were
excluded from the Tg analyses due to positive anti-Tg antibody
results (>100 U/mL). Of the remaining 50 no CND patients, 12
(24.0%) had ablation-Tg levels >5 ng/mL, 11 (22.0%) had levels
from 2-5 ng/mL, and 27 (54.0%) had levels <2 ng/mL (Fig. 2).
The 48 CND patients were analyzed as those with (N=18) or with-
out (N=30) pathologic central nodal metastases. While the pro-
portion of patients with a serum stimulated ablation-Tg level >5
ng/mL appeared to be higher in the node-positive compared to
the node-negative group (4/18 vs. 1/30, respectively), this dif-
ference did not reach statistical significance (P=0.058). The same
analysis with using an ablation-Tg threshold level of <2 ng/mL
showed the proportion of such patients was similar in both the
node-positive and node-negative groups (12/18 vs. 24/30, respec-
tively, P=0.325).
On the analyses of the control-Tg levels, 4 no CND patients
and 3 CND patients were excluded due to positive anti-Tg levels
(>100 U/mL). The proportion of patients with serum stimulated
control-Tg levels >2 ng/mL did not significantly differ between
the no CND or the node-positive CND patients and the node-
negative CND patients (5/49 or 2/18 vs. 1/27, respectively,
P>0.1) (Fig. 3). 
Three patients experienced recurrence during follow-up (2 no
CND patients and 1 node-positive CND patient), as confirmed
by ultrasonography-guided fineneedle aspiration cytology. The
2 no CND patients had recurrences in the thyroid bed and lat-
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Fig. 1. Serum TSH-stimulated Tg levels in patients either undergoing
(CND) or not undergoing (no CND) central node dissection (CND). The
ablation- and control-Tg levels were measured prior to radioactive iodine
therapy (RAI) and at follow-up 6-12 months after RAI, respectively. The
mean Tg levels were higher in the no CND and node-positive CND
patients than in node-negative CND patients: ablation-Tg, 5.780 and
3.367 ng/mL vs. 1.059 ng/mL, P=0.054; control-Tg, 2.078 and 0.904
ng/mL vs. 0.447 ng/mL, P=0.319.
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Fig. 2. Serum TSH-stimulated Tg levels prior to radioactive iodine ther-
apy. The ablation-Tg levels were categorized as >5.0 ng/mL, 2.0-5.0
ng/mL and <2.0 ng/mL. The central neck dissection (CND) patients
were analyzed as those with or without occult metastases to the cen-
tral neck compartment. 
<2
Ablation-Tg 
( g/L)
2-5
>5eral neck. The 1 node-positive CND patient had a recurrence in
the lateral neck. The ablation-Tg levels and control-Tg levels of
all the patients with recurrences were as high as >8.0 ng/mL. 
DISCUSSION
The present study found that CND was not associated with any
increase in postoperative complications. The incidence of hypo-
calcemic was the same for both CND and no CND groups, sug-
gesting that exploration of the central neck compartment did not
lead to increased damage to the parathyroid glands during
CND. These findings are in disagreement with those of others
researchers who reported that while CND was not associated
with an increased risk of postoperative vocal fold paralysis, it
was linked to a higher rate of transient and permanent hypo-
parathyroidism (16, 17). Such findings have resulted in CND
not being routinely used in all PTMC patients. However, the
current study shows that CND can be safely performed by an
experienced surgeon and this procedure does not increase the
risk of surgical morbidity. 
In the current study, occult metastasis to the central neck com-
partment was found in 37.5% of the CND patients with no clin-
ical nodal metastasis, which is consistent with the other recent
reports (5, 18). The pathologic finding of PTMC having a high
proclivity for regional metastases seems to justify performing
routine CND in these patients. A recent study of 600 PTMC
patients who underwent CND found there was no significant dif-
ference for disease-free survival between the patients who were
positive (43%) or negative (57%) for central nodal metastasis
(18). Another study asserted that nodal recurrence did not dif-
fer between the prophylactic dissection group and the no-dissec-
tion group, prophylactic CND for PTMC is not beneficial to the
patients with no palpable lymphadenopathy.
A major issue of PTMC treatment is the prognostic value of
microscopic lymph node involvement. Measurement of the serum
TSH-stimulated Tg levels is an important method for detecting
the presence of residual or recurrent malignant thyroid tissue dur-
ing follow-up. The meaning of the Tg levels at RAI is still debat-
able because the thyroid remnants and untreated occult metas-
tasis contribute to Tg synthesis and therefore, the increased Tg
levels. However, a prior report suggested that the ablation-Tg
levels were well correlated with the control-Tg levels, and that
levels >2.0 ng/mL were highly associated with persistent or recur-
rent disease in the low-risk patients with well-differentiated thy-
roid carcinoma (15). Therefore, we used both the ablation-Tg
and control-Tg levels for predicting recurrences. The ablation-Tg
levels appeared to be higher in the controls or the CND patients
with nodal metastases than that in the CND patients without nodal
metastases. In addition to the pathologic information on nodal
metastases in PTMC patients, this may also suggest a role for CND
in planning RAI after surgery.
Recent studies have investigated whether the control-Tg val-
ues can predict recurrent and persistent disease (19, 20). The
current study found that control-Tg levels did not differ among the 3
groups, and that the recurrence rate was very low. Moreover,
no recurrence was found in any of the CND patients without
occult nodal metastasis, suggesting that this group has a good
prognosis and there is no need for high-dose RAI. Thus, CND
may have a role in determining the plan for postoperative RAI
and also the patient’s prognosis.
The present study data allowed us to investigate whether RAI
was sufficient to remove occult metastasis. For the control patients,
44.0% had a stimulated Tg level above 2 ng/mL prior to RAI,
while only 10.2% were above 2 ng/mL at 6-12 months after
RAI. This result suggests that RAI may be an effective method
for ablating the remnant thyroid tissue or disease. However,
the potential benefits of RAI on lowering the disease recurrence
rate and the mortality rate of PTMC patients remains as a contro-
versial issue (9, 21-23), and no randomized, controlled clinical
trials have yet been performed on a large number of patients.
Furthermore, RAI has side effects, including radiation sialadeni-
tis in up to 40% of patients, with the incidence linked to the
dose of radioiodine (24). The recent data suggests that low-risk
patients with PTMC do not benefit from RAI (23). Thus, CND
may help discriminate between the patients with and without
PTMC-associated metastatic neck diseases and so this can abro-
gate the necessity of high-dose RAI for the low-risk patients. 
The present study may have been limited by its retrospective
non-randomized design. The decision to perform a CND may
have been skewed by the surgeon’s preference. However, the
general demographic and pathologic data were comparable be-
tween the control and CND groups. The study also included more
than 100 PTMC patients with a clinical N0 neck, which is a large
number of patients and it is more than sufficient for making be-
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Fig. 3. The serum TSH-stimulated Tg levels at follow-up 6-12 months
after radioactive iodine therapy. The control-Tg levels were categorized
as >2.0 ng/mL, 1.0-2.0 ng/mL and <1.0 ng/mL. The central neck dis-
section (CND) patients were analyzed as those with or without occult
metastases to the central neck compartment.
<1
Control-Tg 
( g/L)
1-2
>2tween-group comparisons. A relatively short follow-up period
may also have been a limitation, and it may have affected the
findings regarding recurrence or survival. The present data showed
that the serum TSH-stimulated Tg levels were predictive of recur-
rence, and now a larger study with a longer follow-up period is
warranted to confirm our results. 
CONCLUSION
The present study found that occult metastasis to the central com-
partment is a common event in PTMC patients. A CND provides
pathologic information on nodal metastases, which may assist the
postoperative RAI planning. It appears that the stimulated Tg
levels at RAI and follow-up may help predict recurrence, and while
this observation did not reach statistical significance in this study,
we believe it may reach significance in a larger study. The long-
term benefit of CND on recurrence and survival ultimately remains
questionable. However, our present findings indicate that these
questions may be answered by a longer follow-up of these patients.
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